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Abstract In this study, we compared the efficacy and
tolerability of the combination of paracetamol 1,000 mg ?
caffeine 130 mg (PCF) with sumatriptan 50 mg (SUM) in
migraine attacks. This was a multi-center randomized
double-blind, double-dummy, cross-over controlled trial.
The efficacy was assessed by the sum of pain intensity
differences, the curve of mean pain intensity, the number of
pain free at 2 h, and the total pain relief. Tolerability was
assessed by recording adverse events within 4 h after drug
assumption and evaluating the global judgement of
patients. The comparison of these parameters did not show
differences between the two drugs which resulted abso-
lutely overlapping in pain relief and patients evaluation.
In conclusion, we confirm the efficacy and safety of PCF
such as SUM in the treatment of migraine attacks.
Keywords Migraine  Acute treatment 
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Introduction
Migraine is an intermittent neurological disorder, affecting
10–12 % of the western population. In population studies,
the prevalence of migraine is approximately 17 % in
women and 6 % in men [1]. Migraine is a common, dis-
abling headache disorder, with considerable social and
economic impact, and is currently ranked by the World
Health Organization as 19th among causes of years lived
with disability [2, 3].
Migraine is diagnosed according to the criteria of the
International Headache Society (IHS) as a recurrent head-
ache disorder manifesting with attacks lasting 4–72 h.
Typical characteristics of the migraine headache are unilat-
eral location, pulsating quality, moderate or severe intensity,
aggravation by routine physical activity, and association
with nausea and/or photophobia, and phonophobia [4].
Acute migraine attacks can be treated with either unspe-
cific drugs such as acetyl salicylic acid and NSAIDs or
specific medicines like triptans and ergot alkaloids. In addi-
tion, prokinetic drugs and neuroleptics may be useful [5–7].
Triptans are migraine-specific drugs binding to serotonergic
receptors. They are considered first-line therapy for moder-
ate-severe migraine, or mild-moderate attacks unresponsive
to nonspecific analgesics [7]. Triptans are more effective in
injectable than in oral formulations and should be avoided in
patients with a risk for vascular complication [7]. NSAIDs
such as ketorolac and naproxen have the advantage of being
appropriate for patients with vascular risk factors and they do
not cause sedation [7, 8]. NSAIDs are generally well toler-
ated and may provide benefit even when given late in the
migraine attack [8]. However, gastric irritation and occa-
sionally ulceration may complicate treatment with aspirin or
other NSAIDs, even when they are used intermittently [7, 8].
The combination of paracetamol and metoclopramide was
showed to be superior to paracetamol alone in migraine [9],
Paracetamol ? caffeine is an useful alternative to NSAID for
tension-type headache (TTH); it was compared with placebo
in three high-quality studies, showing its superiority over
placebo as well as a good tolerability [10, 11].
Till date there is only a large-scale study comparing
the early treatment of an association of migraine of
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sumatriptan 50 mg and a combination of aspirin ? acet-
aminophen ? caffeine [12]. This study has been discussed
by some authors for some methodological criticisms
[13, 14]. Studies comparing paracetamol ? caffeine versus
sumatriptan at low dose for the treatment of mild-severe
migraine treatment are lacking.
The aim of this study was to evaluate the association of
paracetamol 1,000 mg ? caffeine 130 mg (PCF) to treat
acute migraine attacks and compare the efficacy and safety




This multi-center study was conducted between May 2011
and April 2012 in two Italian Headache Centers recruiting
108 outpatient volunteers of both genders (one-third male,
age 18–62) with a clinical history of episodic migraine
fulfilling the following inclusion criteria:
• Diagnosis of migraine fulfilling ICHD-II criteria for
migraine with or without aura.
• Mean frequency of 2–8 attacks per month.
• If female, adequate contraception in women of fertile
age.
• Daily consumption of at least two cups of coffee.
• Medical history and clinical parameters inconsistent
with organic or psychiatric disorders associated with
headaches.
Exclusion criteria were:
• Declared hypersensitivity or allergy to paracetamol or
sumatriptan.
• Presence of chronic migraine or headache, or medica-
tion overuse headache.
• Post-traumatic headache.
• Past or present earth ischemia or myocardial infarction,
cerebral ischemic attacks, peripheral vascular diseases,
hepatic or renal diseases, mail, severe or uncontrolled
hypertension, phenylketonuria, hemolytic anemia.
• Treatment with anticoagulants or antiplatelet drugs.
• Drugs and alcohol abuse, or psychiatric diseases.
• Coagulation disorders, peptic ulcer disease, pancreatic
disease, clinically significant renal or hepatic disease,
blood hypertension, mild/moderate kidney or liver
failure, Gilbert’s syndrome.
The study was conducted, following good clinical
practice standards and in accordance with the Declaration
of Helsinki (Tokyo version 2004) and stated after inde-
pendent ethics committee approval for each investigator
(Paracaf-emi-010 Code EudraCt 2010-019083-36). Prior to
enrolment the patients gave their written informed consent;
they were allowed to terminate participation in the trial at
any time, without giving reasons. This trial complies with
the guidelines for trials of drug treatments in migraine of
the IHS [15].
Study design and treatments
Primary objectives of the study were to show the efficacy of
the association of paracetamol 1,000 mg and caffeine
130 mg in reducing pain in migraine attacks, and the
tolerability of this combination in migraine treatment.
Secondary objective was to demonstrate the non-inferiority
of the PCF association versus SUM in a comparison
between these two treatment in migraine attacks.
This was a phase IV study randomized, double-dummy,
cross-over, drug-controlled trial. We decided to exclude
placebo due to some ethical reasons: this a phase IV study,
comparing two well-known active drugs, and our ethical
committee did not allow private patients of an active
treatment in a study aimed to compare two active drugs.
After obtaining the signature on the informed consent
form, the patients were required to treat three subsequent
consecutive migraine attacks with the investigational
study medications, according to a randomized cross-over
sequence computer generated using Microsoft_Access
2003. Each patient was randomly allocated to assume
either one PCF and two SUM, or two PCF and one SUM in
a randomized sequence treatment. Eligible patients were
assigned in sequential order of entry. Access to the ran-
domisation code was strictly controlled and the treatment
assignment remained unknown to all parties involved in the
trial until database formal lock.
Subjects in all treatment groups received three identical
boxes (numbered progressively from 1 to 3, to indicate the
exact order in which they should have been used) con-
taining: one soft gel capsule containing one tablet of pla-
cebo or sumatriptan 50 mg and one sachet containing
paracetamol 1,000 mg ? caffeine 130 mg or one sachet
containing the excipients and flavor as the active drug.
Blinding was ensured using matched trial supplies, iden-
tical in color, size, shape, and taste. At each migraine attack
patients would have to take one soft gel capsule and one
sachet at the same time. The trial medication was to be taken
when the headache occurred, and when the patients would
normally have taken their usual analgesic. Other than study
medication, patients received rescue medication (usual med-
ication for each patient), to be taken 3 h after the adminis-
tration of the trial medication, if the pain lasted over the 2 h.
At baseline visit, a complete patients’ medical history
and concomitant treatments were recorded, vital signs were
measured, and a physical examination was performed by
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the investigator. Patients were required to record in a
headache diary, the date and time of drug ingestion, pain
intensity before treatment, pain intensity, pain relief, and
adverse events (AEs) after treatment recorded at 1, 2, 3, 4,
and 24 h. At the end of 4-h measurement interval or at the
time of use of rescue medication, the patients had to record
the presence and intensity of AEs. A global judgment of
the treatment was also required. The same procedures were
repeated for the two subsequent migraine attacks.
Outcomes
Safety and tolerability were evaluated by comparing vital
signs at screening and final visits and by recording AEs.
AEs could be recorded by the investigator or by the patient
filling in a symptom check-list (including nervousness,
palpitation, insomnia, dizziness, abdominal pain, dyspep-
sia, nausea, vomiting, drowsiness, and fatigue) hourly for
4 h after the study medication ingestion. AEs severity was
determined by subjective evaluation of the patient and
classified as mild (signs or symptoms easily tolerated),
moderate (discomfort sufficient to cause interference with
normal activities), and severe (incapacitating with inability
to do work or undertake normal activity).
A global assessment of tolerability was expressed by the
patient, using a 5-point verbal rating scale (VRS: ‘excel-
lent’, ‘very good’, ‘good’, ‘sufficient’, and ‘poor’).
To assess treatments’ efficacy, intensity of pain (on a
4-point scale: 0 ‘absent’, 1 ‘mild’, 2 ‘moderate’, 3 ‘severe’)
and pain relief (on a 5-point scale: 0 ‘no relief’, 1 ‘little
relief’, 2 ‘some relief’, 3 ‘much relief’, 4 ‘complete relief’)
were evaluated hourly during the 4-h post-dose period.
Based on these two variables, the following parameters
were calculated:
– For each patients the sum of pain intensity differences
(SPID) was calculated as the sum of differences
between pre-dose assessment and every post-dose
assessment.
– Total pain relief (TOTPAR), calculated as the sum of
every post-dose assessment.
Statistical analysis
Migraine is a disease with a large inter-individual vari-
ability to treatment; to reduce this bias the trial is con-
ducted following a double-blind controlled double-dummy
cross-over study versus an active drug.
The study was powered to test the primary hypothesis,
namely that paracetamol 1,000 mg ? caffeine 130 mg
would be non-inferior to SUM as regards the proportion of
patients within the 4-h post-dose period.
Assuming a reduction of pain intensity, calculated in a
4-point scale, as recommended by IHS, within 4 h as
1.2 ± 1.3 (SD) in the control study group, we assumed that
PCF will be non-inferior when the mean will be D = ±0.5.
Giving an unilateral a = 0.025 and a 80 % power 110 case
for treatment will be enough for statistical analysis.
According to study protocol all the randomized patients
who took at least one of the treatments (intention-to-treat,
ITT) were evaluated.
Data missing for any scheduled evaluation was replaced
by the last observation carried forward (LOCF) procedure.
The tolerability endpoints were evaluated using ITT pop-
ulations; ITT population was employed for efficacy anal-
yses. Descriptive statistics on population was used for
demographic and baseline characteristics.
The Fisher exact test (with a 90 % confidence interval)
was used to compare the percentage of patients who recor-
ded AEs after each treatment. Besides those recorded by
patients in the 4-h post-dose period, all the AEs were clas-
sified by the investigator on the basis of treatment received,
system involved, severity, and correlation with the investi-
gational medication. The analysis of variance was used to
evaluate the differences of vital signs respect to baseline.
The analysis of variance was used to evaluate SPID and
TOTPAR. The patient’ preference for one of the treatments
was reported as a distribution of frequency. Other statistical
tests were used when appropriate.
Results
108 caucasian patients participated in the study and 92 took
at least one of the treatment, whereas 16 patients who filled
inclusion criteria did not take any medication. In three cases,
the subjects in the following days after randomization
explicitly refused to continue the study; In the other 13 cases,
when the patients where recalled after 2 months for the
second scheduled visit, they refused to continue the protocol
for personal reasons. Two patients assumed one treatment
and eight subjects assumed two treatments; so the ITT pop-
ulation was of 92 cases and were evaluated for efficacy and
tolerability for both the treatments. Globally 264 migraine
attacks were evaluated, 131 treated with PCF and 133 treated
with SUM. The demographic characteristics and headache
history of the patients are summarized in Table 1.
With regard to the familial history, 66 (72 %) of cases
referred a first-order relative suffering from headache.
Efficacy
The comparison between the two treatments did not show
any difference in pain intensity at baseline both as absolute
values and for a Chi square test (p = 0.72).
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Figure 1 reports the time course of mean pain intensity
for PCF and SUM treatment, while the sum of SPID and
the TOTPAR in the T 0–4 h period is illustrated in Table 2.
Data showed that both the treatments are effective with
respect to the baseline, but there were no differences
between the treatments.
The time course of TOTPAR is reported in Fig. 2, where
similar results are showed. Rescue medication was assumed in
38 % of PCF treatments and 45 % of SUM treatment, without
significant differences (Fisher exact test: p = 0.3308), even
looking at the timing of assumption, i.e., before or 3 h after
the first treatment (Fisher exact test: p = 0.2245).
Safety
Taking into account the ITT population and the 264 con-
sidered attacks, the number of side effects is reported in
Table 3. In about half of recorded attacks, we did not
register adverse events (0.9 ± 1.2 and 1.1 ± 1.3 for PCF
and SUM, respectively), without differences between the
treatments (t test: p = 0.156). The intensity of side effects
was always slight or moderate, all side effects disappeared
spontaneously and none requested any modification of
scheduled treatment. The only difference between the
treatments was a slight increase of referred fatigue in
patients assuming SUM.
In Table 3 the global assessment of efficacy and toler-
ability is referred as reported by patients. In Table 4 the
number of side effects is reported, and in Table 5 the types
of side effects recorded are reported.
Table 1 Demographic data and headache history (ITT, n = 92)
Male 31 (33.6 %)
Female 61 (66.3 %)
Age (years)
(mean ± SD)
Male 33.6 ± 10.5
Female 35.6 ± 9.6
Headache Index 4 ± 3.5
Usual pain intensity
Mild 20 (22 %)
Moderate 49 (53 %)
Severe 23 (25 %)
BMI \18.5 18.5–24.9 25.0–29.9 [30
Male (%) – 46.2 46.2 7.7
Female (%) 5.9 78.4 11.8 3.9
Headache index = number of day with headache in the observed
period
Pain intensity = in a 0–3 scale
Fig. 1 Time course of pain intensity. In both treatment groups since
at time T = 1 h in both groups there was a highly significant
difference versus basal time (paired t test: p \ 0.0001)
Table 2 Sum of pain intensity differences (SPID) and total pain
relief (TOTPAR) in the 4-h observation period for the ITT dataset
(n = 264)
PCF SUM All t test
SPID
Baseline intensity 2.1 ± 0.7 2.1 ± 0.8 2.1 ± 0.8
Mean ± SD 3.2 ± 3.8 3.2 ± 3.7 3.2 ± 3.8 p = 0.88
TOTPAR
Mean ± SD 7.0 ± 3.6 7.4 ± 3.6 7.2 ± 3.6 p = 0.48
SD standard deviation
ANOVA for SPID and TOTPAR showed a positive independent
significant variable for intensity of headache at baseline (p \ 0.001),
while no difference between type of treatment (p = 0.8849)
Fig. 2 Time course of the total pain relief (TOTPAR) in the ITT
dataset. In both treatment groups, since time T = 0–1 h there was a
highly significant difference versus basal time (paired t test:
p \ 0.0001)
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Discussion
Migraine is a widespread condition that in the majority of
cases is self-treated by patients, so the use of safe and
effective drugs is a reasonable basis for selecting
medicines.
Many studies have been conducted to show the efficacy
of combination drugs in the treatment of migraine attacks
[12, 16, 17].
In a three double-blind, randomized, parallel-group,
single-dose, placebo-controlled studies Lipton showed that
the combination of acetaminophen, aspirin, and caffeine
was highly effective for the treatment of migraine headache
pain as well as for alleviating the nausea, photophobia,
phonophobia, and functional disability associated with
migraine attacks. This drug combination also has an
excellent safety profile and is well tolerated [16].
In 2005, Goldstein compared a combination of non-
prescription migraine medication (acetaminophen 500 mg,
aspirin 500 mg, and caffeine 130 mg) with a prescription
migraine product (50 mg sumatriptan) in a randomized,
controlled clinical trial in which subjects were treated at
the first sign of a migraine attack. He concluded that the
combination of acetaminophen, aspirin, and caffeine was
significantly more effective (p [ 0.05) than sumatriptan in
the early treatment of migraine, as shown by superiority in
summed pain intensity difference, pain relief, pain intensity
difference, response, sustained response, relief of associ-
ated symptoms, use of rescue medication, disability relief,
and global assessments of effectiveness [12].
More recently Diener [17] in a post hoc analysis
reported that the fixed combination of ASA (250 mg),
paracetamol (200 mg), and caffeine (50 mg) is effective
and well tolerated in a broad spectrum from mild-to-severe
migraine and TTH severity independent of the headache
diagnosis.
Prior confirmed in a double-blind study that acetami-
nophen 1,000 mg is an effective and well-tolerated treat-
ment for episodic and moderate migraine headache. In
addition, acetaminophen generally provided a beneficial
effect on associated symptoms of migraine including nau-
sea, photophobia, phonophobia, and functional disability
[18].
we some years ago, confirmed the efficacy of the acet-
aminophen ? caffeine association in TTH [11].
In fact, paracetamol exerts its analgesic activity through
a direct effect on the central nervous system [19], at least in
part mediated by the serotonergic system [20, 21]. Due to
its scarce inhibition of peripheral cyclooxygenase: it is
better tolerated at gastrointestinal level than NSAIDs, it is
only a weak inhibitor of platelets aggregation and does not
alter the bleeding time [22].
The association with caffeine is relevant because of the
well-known antagonism of adenosine A(2A) and A(2B)
receptors, as well as the inhibition of cyclooxygenase
activity at some sites, may explain intrinsic antinociceptive
and adjuvant actions. When combined with morphine,
caffeine can augment, inhibit or have no effect depending
on the dose, route of administration, nociceptive test, and
species. Low doses of caffeine given systemically inhibit
antinociception by several analgesics (acetaminophen,
amitriptyline, oxcarbazepine, cizolirtine), probably
reflecting block of a component of action involving aden-
osine A(1) receptors. Clinical studies have demonstrated
adjuvant analgesia, as well as some intrinsic analgesia, in
the treatment of headache conditions, but not in the treat-
ment of post-operative pain [23], and Diener [24] showed
the superiority of the combinations containing caffeine
over the association of aspirin and paracetamol alone.
Because the cross-over there were no differences
between groups, but it was interesting to note that males
showed a BMI significantly superior to the females (Fisher
exact test: p \ 0.001).
Comparing the two treatments, there was a complete
overlapping in the efficacy items both for SPID and
TOTPAR.
Analyzing the time course of the mean of pain intensity
it is interesting to note that at the 24 h almost all patients
had resolved their migraine attacks, whereas 41 % of them
should assume a rescue medication.
Rescue medication was assumed within both treatments
without differences, even when we compared the time of
assumption: in fact, there was a small and non-significant
difference between SUM treatment where patients assumed
in the 38 % of cases the rescue drug at the time 3 versus a
21 % of assumption in PCF treatments (Fisher exact test:
p = 0.22).
Table 3 Assessment of efficacy and tolerability for each treatment
(n = 264)
PCF, n (%) SUM, n (%)
Efficacy
Complete relief 97 (74.1) 96 (72.2)
Much relief 8 (6.5) 9 (6.7)
Some relief 7 (5.3) 8 (6.1)
Little 8 (6.5) 9 (6.7)
No relief 11 (8.4) 11 (8.3)
Tolerability
Excellent 53 (40.4) 48 (36.4)
Very good 34 (26.2) 33 (24.6)
Good 16 (12.2) 24 (17.8)
Sufficient 17 (12.8) 15 (11.5)
Poor 11 (8.4) 13 (9.7)
Fisher exact test p = 0.98 for efficacy and p = 0.43 for tolerability
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The evaluation of efficacy and tolerability in the
patient’s report again showed a complete equivalence of
the treatments. In addition, about 80 % of patients for each
treatment declared much or complete relief, and a similar
percentage referred a very good/excellent tolerability. Even
this parameter did not show the differences between the
treatments.
We reported the number of total side effects (Table 4)
and the more frequent types in Table 5. In this table, there
was a significant increase of fatigue in patients assuming
SUM compared with cases assuming PCF: This datum
result isvery low in the PCF treatment whereas the % in the
SUM treatment is similar to the placebo group in our
previous study [11].
In conclusion, this trial could have relevant implications
for the clinical practice, showing that the simple combi-
nation of paracetamol 1,000 mg ? caffeine 130 mg seems
to be as efficient and safe as sumatriptan 50 mg by mouth,
and this could be an important indication for patients suf-
fering from migraine who cannot assume triptans.
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